Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders

Shamsah B. Sonawalla, Maya K. Spillmann, Andrea R. Kolsky, Jonathan E. Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared with major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in depressive symptoms and anxiety levels in outpatients with major depression with comorbid anxiety disorder following 12 weeks of open treatment with fluvoxamine. Method: We enrolled 30 outpatients (mean ± SD age = 39.4 ± 11.3 years; 16 women and 14 men) with DSM-IV major depressive disorder accompanied by one or more current comorbid DSM-IV anxiety disorders in our study. Patients were treated openly with fluvoxamine initiated at 50 mg/day, with an upward titration to a maximum of 200 mg/day (mean ± SD dose = 143 ± 45 mg/day). Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Clinical Global Impressions- Severity of Illness (CGI-S) and Improvement (CGI-I) scales for both depression and anxiety. Intent-to-treat analysis was used to assess outcome. Results: The mean ± SD number of comorbid anxiety disorders per patient was 2.1 ± 1.1. Following fluvoxamine treatment, the mean ± SD HAM-D-17 score dropped from 20.2 ± 3.3 to 11.0 ± 7.0 (p < .0001). The mean ± SD depression CGI-S score dropped from 4.0 ± 0.6 to 2.4 ± 1.1 (p < .0001), and the mean ± SD anxiety CGI-S score decreased from 4.1 ± 0.8 to 2.5 ± 1.2 (p < .0001). Eighteen (60%) of the 30 patients had CGI-I scores ≤ 2 for both anxiety and depression at endpoint, with 53% showing a ≥ 50% reduction in HAM-D-17 scores at endpoint. Conclusion: Although preliminary, our findings suggest that fluvoxamine is effective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms: Further double-blind, placebo- controlled trials are needed, in a larger sample, to confirm our findings.

Original languageEnglish (US)
Pages (from-to)580-583
Number of pages4
JournalJournal of Clinical Psychiatry
Volume60
Issue number9
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Fluvoxamine
Anxiety Disorders
Depression
Anxiety
Therapeutics
Outpatients
Diagnostic and Statistical Manual of Mental Disorders
Major Depressive Disorder
Antidepressive Agents
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Sonawalla, S. B., Spillmann, M. K., Kolsky, A. R., Alpert, J. E., Nierenberg, A. A., Rosenbaum, J. F., & Fava, M. (1999). Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Journal of Clinical Psychiatry, 60(9), 580-583.

Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. / Sonawalla, Shamsah B.; Spillmann, Maya K.; Kolsky, Andrea R.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: Journal of Clinical Psychiatry, Vol. 60, No. 9, 09.1999, p. 580-583.

Research output: Contribution to journalArticle

Sonawalla, SB, Spillmann, MK, Kolsky, AR, Alpert, JE, Nierenberg, AA, Rosenbaum, JF & Fava, M 1999, 'Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders', Journal of Clinical Psychiatry, vol. 60, no. 9, pp. 580-583.
Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Journal of Clinical Psychiatry. 1999 Sep;60(9):580-583.
Sonawalla, Shamsah B. ; Spillmann, Maya K. ; Kolsky, Andrea R. ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. In: Journal of Clinical Psychiatry. 1999 ; Vol. 60, No. 9. pp. 580-583.
@article{af854ce06041408b9fd98f4f67c506a2,
title = "Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders",
abstract = "Background: Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared with major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in depressive symptoms and anxiety levels in outpatients with major depression with comorbid anxiety disorder following 12 weeks of open treatment with fluvoxamine. Method: We enrolled 30 outpatients (mean ± SD age = 39.4 ± 11.3 years; 16 women and 14 men) with DSM-IV major depressive disorder accompanied by one or more current comorbid DSM-IV anxiety disorders in our study. Patients were treated openly with fluvoxamine initiated at 50 mg/day, with an upward titration to a maximum of 200 mg/day (mean ± SD dose = 143 ± 45 mg/day). Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Clinical Global Impressions- Severity of Illness (CGI-S) and Improvement (CGI-I) scales for both depression and anxiety. Intent-to-treat analysis was used to assess outcome. Results: The mean ± SD number of comorbid anxiety disorders per patient was 2.1 ± 1.1. Following fluvoxamine treatment, the mean ± SD HAM-D-17 score dropped from 20.2 ± 3.3 to 11.0 ± 7.0 (p < .0001). The mean ± SD depression CGI-S score dropped from 4.0 ± 0.6 to 2.4 ± 1.1 (p < .0001), and the mean ± SD anxiety CGI-S score decreased from 4.1 ± 0.8 to 2.5 ± 1.2 (p < .0001). Eighteen (60{\%}) of the 30 patients had CGI-I scores ≤ 2 for both anxiety and depression at endpoint, with 53{\%} showing a ≥ 50{\%} reduction in HAM-D-17 scores at endpoint. Conclusion: Although preliminary, our findings suggest that fluvoxamine is effective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms: Further double-blind, placebo- controlled trials are needed, in a larger sample, to confirm our findings.",
author = "Sonawalla, {Shamsah B.} and Spillmann, {Maya K.} and Kolsky, {Andrea R.} and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "1999",
month = "9",
language = "English (US)",
volume = "60",
pages = "580--583",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders

AU - Sonawalla, Shamsah B.

AU - Spillmann, Maya K.

AU - Kolsky, Andrea R.

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 1999/9

Y1 - 1999/9

N2 - Background: Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared with major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in depressive symptoms and anxiety levels in outpatients with major depression with comorbid anxiety disorder following 12 weeks of open treatment with fluvoxamine. Method: We enrolled 30 outpatients (mean ± SD age = 39.4 ± 11.3 years; 16 women and 14 men) with DSM-IV major depressive disorder accompanied by one or more current comorbid DSM-IV anxiety disorders in our study. Patients were treated openly with fluvoxamine initiated at 50 mg/day, with an upward titration to a maximum of 200 mg/day (mean ± SD dose = 143 ± 45 mg/day). Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Clinical Global Impressions- Severity of Illness (CGI-S) and Improvement (CGI-I) scales for both depression and anxiety. Intent-to-treat analysis was used to assess outcome. Results: The mean ± SD number of comorbid anxiety disorders per patient was 2.1 ± 1.1. Following fluvoxamine treatment, the mean ± SD HAM-D-17 score dropped from 20.2 ± 3.3 to 11.0 ± 7.0 (p < .0001). The mean ± SD depression CGI-S score dropped from 4.0 ± 0.6 to 2.4 ± 1.1 (p < .0001), and the mean ± SD anxiety CGI-S score decreased from 4.1 ± 0.8 to 2.5 ± 1.2 (p < .0001). Eighteen (60%) of the 30 patients had CGI-I scores ≤ 2 for both anxiety and depression at endpoint, with 53% showing a ≥ 50% reduction in HAM-D-17 scores at endpoint. Conclusion: Although preliminary, our findings suggest that fluvoxamine is effective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms: Further double-blind, placebo- controlled trials are needed, in a larger sample, to confirm our findings.

AB - Background: Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared with major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in depressive symptoms and anxiety levels in outpatients with major depression with comorbid anxiety disorder following 12 weeks of open treatment with fluvoxamine. Method: We enrolled 30 outpatients (mean ± SD age = 39.4 ± 11.3 years; 16 women and 14 men) with DSM-IV major depressive disorder accompanied by one or more current comorbid DSM-IV anxiety disorders in our study. Patients were treated openly with fluvoxamine initiated at 50 mg/day, with an upward titration to a maximum of 200 mg/day (mean ± SD dose = 143 ± 45 mg/day). Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Clinical Global Impressions- Severity of Illness (CGI-S) and Improvement (CGI-I) scales for both depression and anxiety. Intent-to-treat analysis was used to assess outcome. Results: The mean ± SD number of comorbid anxiety disorders per patient was 2.1 ± 1.1. Following fluvoxamine treatment, the mean ± SD HAM-D-17 score dropped from 20.2 ± 3.3 to 11.0 ± 7.0 (p < .0001). The mean ± SD depression CGI-S score dropped from 4.0 ± 0.6 to 2.4 ± 1.1 (p < .0001), and the mean ± SD anxiety CGI-S score decreased from 4.1 ± 0.8 to 2.5 ± 1.2 (p < .0001). Eighteen (60%) of the 30 patients had CGI-I scores ≤ 2 for both anxiety and depression at endpoint, with 53% showing a ≥ 50% reduction in HAM-D-17 scores at endpoint. Conclusion: Although preliminary, our findings suggest that fluvoxamine is effective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms: Further double-blind, placebo- controlled trials are needed, in a larger sample, to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=0032848041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032848041&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 580

EP - 583

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 9

ER -